Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Ovarian Neoplasms

  Free Subscription


2 BMC Cancer
1 Br J Cancer
3 Clin Cancer Res
6 Gynecol Oncol
1 Int J Cancer
2 Int J Gynaecol Obstet
2 Int J Oncol
1 J Clin Oncol
1 Proc Natl Acad Sci U S A
1 Tumour Biol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BMC Cancer

  1. KIM SI, Lee HC, Yoon HK, Kim HS, et al
    Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma.
    BMC Cancer. 2022;22:965.
    PubMed         Abstract available

  2. CHEN YA, Lu CY, Cheng WF, Kuo KT, et al
    An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids.
    BMC Cancer. 2022;22:967.
    PubMed         Abstract available

    Br J Cancer

  3. BEINSE G, Just PA, Le Frere Belda MA, Laurent-Puig P, et al
    Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    Br J Cancer. 2022 Jun 25. pii: 10.1038/s41416-022-01900.
    PubMed         Abstract available

    Clin Cancer Res

  4. GREEN DS, Ning F, Duemler A, Myers TG, et al
    Intraperitoneal monocytes and interferons as a novel cellular immunotherapy for ovarian cancer: mechanistic characterization and results of a phase I clinical trial.
    Clin Cancer Res. 2022 Sep 13. pii: 709187. doi: 10.1158/1078-0432.CCR-22-1893.
    PubMed         Abstract available

    Multi-omics uncovering different faces of Clear Cell Ovarian Cancer.
    Clin Cancer Res. 2022 Sep 12. pii: 709169. doi: 10.1158/1078-0432.CCR-22-2365.
    PubMed         Abstract available

  6. FISHER NC, Byrne RM, Leslie H, Wood C, et al
    Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data.
    Clin Cancer Res. 2022 Jul 6. pii: 706888. doi: 10.1158/1078-0432.CCR-22-1102.
    PubMed         Abstract available

    Gynecol Oncol

  7. LI N, Zhu X, Nian W, Li Y, et al
    Blood-based DNA methylation profiling for the detection of ovarian cancer.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00480.
    PubMed         Abstract available

  8. VAN STEIN RM, Engbersen MP, Stolk T, Lopez-Yurda M, et al
    Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer.
    Gynecol Oncol. 2022 Sep 7. pii: S0090-8258(22)00576.
    PubMed         Abstract available

  9. MENZIES AV, Usher EC, Hsu FC, Levine EA, et al
    HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients.
    Gynecol Oncol. 2022 Sep 6. pii: S0090-8258(22)00569.
    PubMed         Abstract available

  10. KIM SI, Kim JH, Noh JJ, Kim SH, et al
    Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00483.
    PubMed         Abstract available

  11. VAN DEN HEERIK ASVM, Aiyer KTS, Stelloo E, Jurgenliemk-Schulz IM, et al
    Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials.
    Gynecol Oncol. 2022;166:530-537.
    PubMed         Abstract available

  12. DICKEN BJ, Billmire DF, Rich B, Hazard FK, et al
    Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group.
    Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00417.
    PubMed         Abstract available

    Int J Cancer

  13. ZHONG GC, Zhu Q, Cai D, Hu JJ, et al
    Ultra-processed food consumption and the risk of pancreatic cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Int J Cancer. 2022 Sep 12. doi: 10.1002/ijc.34290.
    PubMed         Abstract available

    Int J Gynaecol Obstet

  14. BARAKE C, Atwani R, Jaafar N, Tamim H, et al
    Appropriateness of hysterectomies at the time of surgical removal of presumed benign adnexal masses.
    Int J Gynaecol Obstet. 2022 Jan 22. doi: 10.1002/ijgo.14110.
    PubMed         Abstract available

  15. CHENG CW, ElSahwi K, Borowsky ME, Aikman N, et al
    Sex Cord Stromal Tumor Presenting with Hair Loss in Postmenopausal Women.
    Int J Gynaecol Obstet. 2022 Jun 2. doi: 10.1002/ijgo.14293.

    Int J Oncol

  16. BJERSAND K, Blom K, Poromaa IS, Stalberg K, et al
    Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome.
    Int J Oncol. 2022;61.
    PubMed         Abstract available

  17. KIM SH, Baek KH
    Ovarian tumor deubiquitinase 6A regulates cell proliferation via deubiquitination of nucleolin and caspase7.
    Int J Oncol. 2022;61.
    PubMed         Abstract available

    J Clin Oncol

  18. DISILVESTRO P, Banerjee S, Colombo N, Scambia G, et al
    Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
    J Clin Oncol. 2022 Sep 9:JCO2201549. doi: 10.1200/JCO.22.01549.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  19. PRAKASH R, Rawal Y, Sullivan MR, Grundy MK, et al
    Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants.
    Proc Natl Acad Sci U S A. 2022;119:e2202727119.
    PubMed         Abstract available

    Tumour Biol

  20. MANGANARO L, Celli V, Viggiani V, Berardelli E, et al
    CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients.
    Tumour Biol. 2022;44:171-185.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.